Mattia Migliari

Mattia Migliari

Auto-generated profile, based on publicly available information

Mattia Migliari

Unit of Vascular Surgery, Department of Nephrological, Cardiac and Vascular Diseases Azienda Ospedaliero‐Universitaria of Modena Modena Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
SGStefano Gennai
Stefano Gennai
GSGioele Simonte
Gioele Simonte
MMMigliari Mattia
Migliari Mattia
NLNicola Leone
Nicola Leone
GIGiacomo Isernia
Giacomo Isernia
RSRoberto Silingardi
Roberto Silingardi

26 December 2023 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MMMattia Migliari
Mattia Migliari
NLNicola Leone
Nicola Leone
GVGian Franco Veraldi
Gian Franco Veraldi
GSGioele Simonte
Gioele Simonte
RSRoberto Silingardi
Roberto Silingardi
GIGiacomo Isernia
Giacomo Isernia

1 February 2022 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
SGStefano Gennai
Stefano Gennai
GSGioele Simonte
Gioele Simonte
MMMattia Migliari
Mattia Migliari
GIGiacomo Isernia
Giacomo Isernia
NLNicola Leone
Nicola Leone
RSRoberto Silingardi
Roberto Silingardi

11 October 2023 in Angiology
Verified
Journal Article
Closed access
Paolo PeriniPaolo Perini
Paolo Perini
MGMauro Gargiulo
Mauro Gargiulo
RSRoberto Silingardi
Roberto Silingardi
SBStefano Bonardelli
Stefano Bonardelli
RBRaffaello Bellosta
Raffaello Bellosta
MFMara Fanelli
Mara Fanelli
We report a multicenter experience of open conversions (OC) for aortic endograft infections (AEI). We retrospectively analyzed all patients who underwent OC for AEI after endovascular aneurysm repair (EVAR), from 1997 to 2021 in 12 Italian centers. The endpoints were as follows: mortality (30-days, in-hospital), major postoperative complications. Follow-up data included: survival, aortic-related complications, infection persistence or reoccurrence. Fifty-eight patients (mean age: 73.8 ± 6.6 years) were included. Median time from EVAR to OC was 14 months (interquartile range 7–45). Thirty-five patients (60.3%) were symptomatic at presentation. Aortic reconstruction was anatomic in 32 patients (55.2%), extra-anatomic in 26 (44.8%). Thirty-day mortality was 31% (18/58). Six additional patients died after 30 days during the same hospitalization (in-hospital mortality: 41.4%). Most common post-operative complications included respiratory failure (38.6%) and renal insufficiency (35.1%). During 28.1 ± 4 months follow-up, 4 aneurysm-related deaths were recorded. Infection re-occurred in 29.4% of the patients. Estimated survival was 50% at 1 year, and 30% at 5 years, and was significantly lower for patients who underwent extra-anatomic reconstructions (37 vs 61% at 1 year, 16 vs 45% at 5 years; log-rank P = .021). OC for AEI is associated with high early mortality. The poor mid-term survival is influenced by aortic complications and infection re-occurrence.

23 November 2020 in Future Cardiology
Verified
Journal Article
Closed access
Pasqualino SirignanoPasqualino Sirignano
Pasqualino Sirignano
RSRoberto Silingardi
Roberto Silingardi
WMWassim Mansour
Wassim Mansour
FAFrancesco Andreoli
Francesco Andreoli
MMMattia Migliari
Mattia Migliari
FSFrancesco Speziale
Francesco Speziale
The unibody (Powerlink/AFX/AFX2) Endovascular AAA device (Endologix Inc., CA, USA) presents a unique design with its long main body and two innate limbs. The device is designed to be deployed and s...

6 April 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
RSRoberto Silingardi
Roberto Silingardi
Pasqualino SirignanoPasqualino Sirignano
Pasqualino Sirignano
FAFrancesco Andreoli
Francesco Andreoli
WMWassim Mansour
Wassim Mansour
MMMattia Migliari
Mattia Migliari
LCLIVE Study Collaborators
LIVE Study Collaborators
Background: Since the introduction of endovascular aortic repair (EVAR) for treatment of abdominal aortic aneurysms (AAAs), progressive improvements in results have been achieved. However, conventional bifurcated stent grafts have been proven to have a nonnegligible risk of failure and secondary intervention, principally due to the lack of adequate proximal sealing. The unique AFX 2 Endovascular AAA System (Endologix, Irvine, CA) unibody device, which provides different sealing and fixation features compared with conventional devices, seems to overcome these limitations. Objective: The aim of this study is to evaluate intraoperative, perioperative, and postoperative results in patients treated with the AFX 2 Endovascular AAA System endografts for elective AAA repair in a large cohort of consecutive patients. Methods: All eligible EVAR patients will be included in this observational, multicenter, prospective, nonrandomized study. The number of patients to be enrolled is 500. Results: The primary endpoint of the study is to evaluate the technical and clinical success of EVAR with unibody endografts in short- (90-day), mid- (1-year), and long-term (5-year) follow-up periods. The following secondary endpoints will also be addressed: operative time, intraoperative radiation exposure, contrast medium usage, AAA sac shrinkage at 12-month and 5-year follow-up, and any potential role of patients’ baseline characteristics and device configuration on primary endpoint. The actual start date of the investigation was November 2019. The final patient is expected to be treated by the end of December 2020, and the estimated study completion date is December 2025. Conclusions: This study will provide verified real-world data on AAAs treated by AFX 2 endografts and followed for a long-term interval. International Registered Report Identifier (IRRID): PRR1-10.2196/16959